Abstract 4338: A Small Panel of Plasma MicroRNAs Distinguishes Transthyretin Amyloid Cardiomyopathy from Other Common Causes of Left Ventricular Hypertrophy
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.4338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Itsuki Osawa und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Early recognition of transthyretin amyloid cardiomyopathy (ATTR-CM) and timely initiation of disease-modifying therapy improve prognosis. However, ATTR-CM remains underdiagnosed, and it is often challenging to distinguish ATTR-CM from other common causes of left ventricular hypertrophy (LVH), such as hypertrophic cardiomyopathy (HCM), hypertensive LVH (hLVH), and aortic stenosis (AS). Hypothesis: A small panel of plasma microRNAs can distinguish ATTR-CM from other common causes of LVH more accurately than the Mayo score, a conventional clinical score to detect ATTR-CM.
Methods
We conducted a multicenter case-control study comprising 167 ATTR-CM cases and 653 controls (294 with HCM, 321 with hLVH, and 38 with AS). We divided the study cohort into training and test sets (1:1). Using the training set, we performed differential expression analyses comparing ATTR-CM with each of the three other causes of LVH. In the training set, we defined the “Plasma MicroRNA Panel” as microRNAs that (1) showed significant expression changes with consistent directionality (i.e., uniformly upregulated or downregulated) across all three comparisons and (2) remained significant after adjustment for the Mayo score. Finally, we developed a LASSO-regularized model using the Plasma MicroRNA Panel in the training set and compared its discriminative performance with the Mayo score in the test set. We also investigated whether the discriminative performance of the Plasma MicroRNA Panel was maintained in each comparison (i.e., with HCM, hLVH, or AS) in the test set.
Results
In the training set, 15 microRNAs met the two criteria above and were included in the Plasma MicroRNA Panel ( Figure 1 ). In the test set, the Plasma MicroRNA Panel outperformed the Mayo score (AUROC [95% CI], 0.96 [0.93-0.98] vs. 0.84 [0.79-0.89]; DeLong’s P < 0.001; Figure 2 ). At the cutoff defined by the Youden index on the ROC curve in the training set, the Plasma MicroRNA Panel achieved sensitivity of 0.91 and specificity of 0.91 in the test set ( Figure 2 ). The discriminative performance of the Plasma MicroRNA Panel was maintained across each of the three comparisons - i.e., comparison with HCM, hLVH, or AS ( Figure 3 ).
Conclusions
In this multicenter study, we identified a small panel of plasma microRNAs that distinguished ATTR-CM from other common causes of LVH with higher discriminatory performance than the Mayo score, suggesting the feasibility of the Plasma MicroRNA Panel as a screening tool for ATTR-CM.
Zitieren
APA
Osawa, I., Akita, K., Fifer, M. A., Tower-rader, A., Teruya, S., Bampatsias, D., Mirabal, A., Maurer, M. S., & Shimada, Y. (2026). Abstract 4338: A Small Panel of Plasma MicroRNAs Distinguishes Transthyretin Amyloid Cardiomyopathy from Other Common Causes of Left Ventricular Hypertrophy. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.4338
Vancouver
Osawa I, Akita K, Fifer MA, Tower-rader A, Teruya S, Bampatsias D, et al. Abstract 4338: A Small Panel of Plasma MicroRNAs Distinguishes Transthyretin Amyloid Cardiomyopathy from Other Common Causes of Left Ventricular Hypertrophy. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.4338
BibTeX
@article{Osawa2026,
author = {Osawa, Itsuki and Akita, Keitaro and Fifer, Michael A and Tower-rader, Albree and Teruya, Sergio and Bampatsias, Dimitrios and Mirabal, Alfonsina and Maurer, Mathew S and Shimada, Yuichi},
title = {Abstract 4338: A Small Panel of Plasma MicroRNAs Distinguishes Transthyretin Amyloid Cardiomyopathy from Other Common Causes of Left Ventricular Hypertrophy},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.4338}
}
EUVIMED